Quadrivalent flu vax on the horizon

A trial of a quadrivalent intramuscular vaccine is currently being conducted by Sanofi Pasteur on around 2000 participants aged nine years or older in Australia and the Philippines, the company confirmed last week.

And a spokesperson for CSL said that CSL Biotherapies was carrying out preclinical work for a future possible quadrivalent vaccine.

Dr Alan Hampson (Hon MD), chairman of the Influenza Specialist Group, said that young children tended to contract more type B infections than older adults, making a vaccine with an extra B virus strain potentially advantageous.

“Mortality is rare but the